# Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

> **NCT01728805** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin, Inc.** · enrollment: 372 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** KW-0761
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT01728805
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2017-03
- **Final completion:** 2021-02-17
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01728805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01728805, "Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01728805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*